Clinically, the substantial increases in CX3CR1+/CD4+ T‐cells observed here are of particular note since inhibition of CX3CR1 to ameliorate atherosclerosis progression is promising,82, 83 as is CX3CR1 modulation in the treatment of CKD.84 The gene discussed is CD4; the disease is atherosclerosis.